Abstract:Abstract Neuromodulation technology, especially Peripheral Nerve Stimulation (PNS), is an important therapeutic tool in the field of pain, and PNS can effectively alleviate a variety of neuropathic pain by targeting the modulation of nociceptive pathways. For herpes zoster trigeminal neuralgia, short-course PNS treatment has demonstrated significant advantages in patients with acute and subacute phases the pain relief rate can reach 70%-85%, the use of analgesic drugs can be reduced by more than 50%, and the complication rate is less than 3%. The mechanism may be related to the inhibition of central sensitization, modulation of inflammatory factor release and promotion of nerve repair. However, existing studies still have limitations include insufficient evidence of long-term efficacy and lack of follow-up data beyond 5 years; lack of uniformity in the criteria for indications and large differences in the response rates of patients with herpes zoster trigeminal neuralgia; and lack of evidence-based basis for the individualized optimization of the stimulation parameters (frequency, pulse width, and intensity). Future research should focus on: conducting multicenter randomized controlled trials to clarify the therapeutic status of PNS in herpes zoster trigeminal neuralgia; establishing an efficacy prediction model by combining functional imaging and molecular markers to more accurately determine the timing of PNS application; and carrying out real-time monitoring of the stimulation parameters and perfecting the feedback loop to explore the optimal stimulation modes and parameter settings for each. Overall, this study aims to improve the comprehensive management of cephalo-facial neuralgia by comparing and summarizing the advantages and disadvantages of the existing treatment modalities in the field of herpes zoster trigeminal neuralgia, and by focusing on the characteristics and research progress of PNS treatment.
